SINTX Receives Notice of Allowance for United States Patent Application for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial
September 09, 2024 08:00 ET
|
SINTX Technologies, Inc.
Salt Lake City, Utah, Sept. 09, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) a leading innovator in ceramic manufacturing, today announced that it has...
Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations
July 18, 2024 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, July 18, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
January 09, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
August 22, 2023 07:31 ET
|
Sixty Degrees Pharmaceuticals
60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individualsTafenoquine...
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
August 15, 2023 07:31 ET
|
Sixty Degrees Pharmaceuticals
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of...
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent
September 06, 2022 10:31 ET
|
Biofrontera Inc.
Company also granted special designation that enables expedited review of a recent U.S. patent application relating to novel PDT illumination protocols WOBURN, Mass., Sept. 06, 2022 (GLOBE...
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
February 28, 2022 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Company in ongoing discussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with...
Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol
December 02, 2021 09:15 ET
|
Biofrontera Inc.
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Citrine Global Subsidiary Files in the U.S. Patent & Trademark Office a Provisional Patent Application for “PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE USE OF CANNABIS & RELATED PRODUCTS”
November 02, 2021 10:42 ET
|
Citrine Global, Corp.
Tel Aviv, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Citrine Global, Corp. (OTCQB: CTGL) is pleased to announce that its subsidiary, Cannovation Center Israel Ltd., has filed in the U.S. Patent &...
Cavitation Technologies Latest Water Treatment U.S. Patent is Approved
January 26, 2021 09:00 ET
|
Cavitation Technologies, Inc
CHATSWORTH, CA, Jan. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Cavitation Technologies, Inc. (OTCQB: CVAT) (BERLIN: WTC) announced that U.S. Patent Application No. 17/066,040, Entitled:...